Eli Lilly and Company (NYSE:LLY) Shares Sold by American Financial Advisors LLC

American Financial Advisors LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,028 shares of the company’s stock after selling 1,671 shares during the quarter. Eli Lilly and Company makes up about 1.6% of American Financial Advisors LLC’s portfolio, making the stock its 22nd biggest holding. American Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $11,092,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $27,000. Retirement Group LLC boosted its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the last quarter. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Finally, Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $19.64 during midday trading on Friday, reaching $726.31. The company’s stock had a trading volume of 3,503,501 shares, compared to its average volume of 3,073,465. Eli Lilly and Company has a fifty-two week low of $369.76 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock’s 50 day simple moving average is $764.24 and its 200 day simple moving average is $658.28. The firm has a market capitalization of $690.11 billion, a PE ratio of 125.67, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.09 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.